Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 6086 (MIR6086) is a short (20-24 nucleotides) non-coding RNA molecule transcribed by RNA polymerase II. It is processed through sequential cleavage by Drosha and Dicer ribonucleases to its mature form. Mature microRNAs, including MIR6086, are loaded into the RNA-induced silencing complex (RISC), where they recognize partially complementary target mRNA sequences and typically suppress protein synthesis either by inhibiting translation or promoting mRNA degradation. MIR6086 is affiliated with the miRNA molecular class, and gene database references associate it with pancreatic cystadenocarcinoma, but comprehensive functional or mechanistic studies specific to MIR6086 are lacking. MicroRNAs like MIR6086 are important regulators in normal physiology and disease, especially in cancer, by affecting cell signaling, proliferation, differentiation, and survival.
Not established; microRNAs act by being incorporated into the RNA-induced silencing complex (RISC) which binds and modulates target mRNAs, most often resulting in translational inhibition or destabilization of the target mRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 6086 (MIR6086).